Enfusion (NYSE:ENFN) Stock Price Down 1.9% – Should You Sell?

Enfusion, Inc. (NYSE:ENFN) shares fell 1.9% during mid-day trading on Tuesday . The company traded as low as $10.12 and last traded at $10.27. 31,225 shares were traded during trading, a decline of 92% from the average session volume of 391,745 shares. The stock had previously closed at $10.47.

Analyst Upgrades and Downgrades

ENFN has been the subject of several analyst reports. Piper Sandler raised their price target on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. Stifel Nicolaus increased their target price on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $10.25.

Enfusion Trading Down 1.6 %

The stock’s fifty day moving average price is $9.95 and its 200 day moving average price is $9.10. The stock has a market cap of $1.32 billion, a P/E ratio of 257.56, a price-to-earnings-growth ratio of 3.98 and a beta of 0.97.

Insider Activity

In other Enfusion news, COO Neal Pawar sold 21,801 shares of Enfusion stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the transaction, the chief operating officer now directly owns 1,143,544 shares of the company’s stock, valued at approximately $11,469,746.32. The trade was a 1.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Bradley Herring sold 24,443 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $10.61, for a total value of $259,340.23. Following the completion of the transaction, the chief financial officer now directly owns 270,503 shares of the company’s stock, valued at approximately $2,870,036.83. This trade represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,918 shares of company stock valued at $484,037. 36.44% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Enfusion

A number of hedge funds have recently added to or reduced their stakes in the stock. Arizona State Retirement System purchased a new position in shares of Enfusion in the second quarter worth approximately $86,000. Harbor Capital Advisors Inc. raised its stake in Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after purchasing an additional 1,315 shares during the period. Belvedere Trading LLC purchased a new position in shares of Enfusion in the third quarter worth $114,000. Paloma Partners Management Co bought a new position in shares of Enfusion during the 3rd quarter valued at about $157,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Enfusion by 27.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after buying an additional 4,239 shares in the last quarter. 81.05% of the stock is currently owned by hedge funds and other institutional investors.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.